Rationale of a phase III study comparing a standard cisplatin regimen (mitomycin/ifosfamide/cisplatin) with cisplatin and gemcitabine in non-small cell lung cancer

被引：0
|
作者：
Tonato, M
Crino, L
Mosconi, AM
机构：
来源：
SEMINARS IN ONCOLOGY | 1997年 / 24卷 / 03期
关键词：
RANDOMIZED TRIAL; ACTIVE REGIMENS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：831 / 835
页数：5
相关论文
共 50 条
  • [21] Gemcitabine, ifosfamide and cisplatin (GIP) in the treatment of non surgical stage III non-small lung cancer (NSCLC).
    De las Peñas, R
    Busquier, I
    Llorente, R
    Munarriz, J
    Lopez, A
    Frau, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S63 - S63
  • [22] Induction chemotherapy with gemcitabine and cisplatin in stage III non-small cell lung cancer
    Rinaldi, M
    Crinò, L
    LUNG CANCER, 2001, 34 : S25 - S30
  • [23] A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer
    Tognoni, A
    Pensa, F
    Vaira, F
    Vigani, A
    Bancalari, L
    Fiasella, L
    Maggiani, R
    Canessa, P
    Pronzato, P
    JOURNAL OF CHEMOTHERAPY, 2001, 13 (02) : 202 - 205
  • [24] Efficacy and toxicity of mitomycin, ifosfamide, and cisplatin (MIP) in patients with inoperable non-small cell lung cancer
    Urban, T
    Bedin, A
    Baud, M
    Chouaid, C
    Febvre, M
    Lebeau, B
    LUNG CANCER, 1996, 14 (01) : 109 - 117
  • [25] A phase II randomised study of gemcitabine-cisplatin (GP) vs mitomycin-ifosfamide-cisplatin (MIP) as neoadjuvant chemotherapy in resectable stage IIIA non-small cell lung cancer (NSCLC)
    Brechot, J
    Saintigny, R
    Azorin, J
    Valeyre, D
    Breau, J
    Morere, J
    LUNG CANCER, 2005, 49 : S92 - S92
  • [26] MITOMYCIN, IFOSFAMIDE AND CISPLATIN IN NON-SMALL CELL LUNG-CANCER - TREATMENT GOOD ENOUGH TO COMPARE
    CULLEN, MH
    JOSHI, R
    CHETIYAWARDANA, AD
    WOODROFFE, CM
    BRITISH JOURNAL OF CANCER, 1988, 58 (03) : 359 - 361
  • [27] A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16)
    Kosmidis, P
    Mylonakis, N
    Fountzilas, G
    Pavlidis, N
    Samantas, E
    Karabelis, A
    Kattis, K
    Skarlos, D
    ANNALS OF ONCOLOGY, 1996, 7 (05) : 517 - 520
  • [28] A phase II study of a modified cisplatin and Gemcitabine regimen in advanced non-small cell lung cancer (NSCLC): An ongoing study
    Gonzalez-Martin, A
    Garcia-Lopez, JL
    Crespo, C
    Lastra, E
    Pedraza, M
    Cerrato, L
    Rios, A
    Moyano, AJ
    Garrido, P
    ANNALS OF ONCOLOGY, 1998, 9 : 98 - 98
  • [29] Stage III-IV non-small cell lung cancer chemotherapy: A prospective non randomized study with mitomycin, ifosfamide and cisplatin (MIP)
    Rubio, I
    Lopez-Vivanco, G
    Barcelo, R
    Mane, JM
    Fernandez, R
    Munoz, A
    ANNALS OF ONCOLOGY, 1998, 9 : 100 - 100
  • [30] Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer
    Postmus, PE
    Giaccone, G
    Debruyne, C
    Sahmoud, T
    Splinter, TAW
    vanZandwijk, N
    SEMINARS IN ONCOLOGY, 1996, 23 (05) : 10 - 13
12345